Mallinckrodt Pharmaceuticals is dedicated to providing safe and effective medications for the treatment of patients with pain and is equally committed to working with policymakers, law enforcement and industry to address the complex issues of opioid addiction and abuse.
Providing relief for people with chronic and acute pain is something Mallinckrodt does exceptionally well. The effective pain management offered by our medicines helps enable patients to stay in the workplace, enjoy interactions with family and friends, and remain an active member of society.
The preferred standard of care must be a balanced, multimodal approach to pain management. Mallinckrodt supports incentives and policies that focus opioid use on cases where adequate pain management cannot be achieved with an alternative therapy, or is not available or inappropriate for a particular patient.
Mallinckrodt advocates for a comprehensive, multi-prong action plan to fight opioid abuse and misuse in the United States. That is why we developed our “Prescription for America’s Opioid Epidemic” – six integrated policy initiatives that we believe, if implemented, would significantly advance the fight against prescription drug abuse and misuse, and make measurable positive contributions to fight the country’s current opioid epidemic.
On May 15, 2019, Mallinckrodt’s shareholders approved a proposal at the 2019 Annual General Meeting requesting the Board assemble a report on the governance measures the Company and SpecGx have implemented since 2012 to more effectively monitor and manage financial and reputational risks related to the opioid crisis in the United States, given SpecGx’s sale of opioid medications and APIs used in the manufacture of opioid medications. The report prepared in response to that shareholder feedback was published on March 31, 2020 and can be found here.
Learn more about Mallinckrodt’s efforts for prescription drug abuse prevention.